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Abstract
Background: Patients who start renal replacement therapy (RRT) for End-Stage Kidney Disease (ESKD) without having
had timely access to specialist renal services have poor outcomes. At one NHS Trust in England, a community-wide
CKD management system has led to a decline in the incident rate of RRT and the lowest percentage of patients
presenting within 90 days of starting RRT in the UK. We describe the protocol for a quality improvement project to
scale up and evaluate this innovation.
Methods: The intervention is based upon an off-line database that integrates laboratory results from blood samples
taken in all settings stored under different identifying labels relating to the same patient. Graphs of estimated glomerular
filtration rate (eGFR) over time are generated for patients <65 years with an incoming eGFR <50 ml/min/1.73 m2 and
patients >65 years with an incoming eGFR <40 ml/min/1.73 m2. Graphs where kidney function is deteriorating are
flagged by a laboratory scientist and details sent to the primary care doctor (GP) with a prompt that further action may
be needed.
We will evaluate the impact of implementing this intervention across a large population served by a number of UK renal
centres using a mixed methods approach. We are following a stepped-wedge design. The order of implementation
among participating centres will be randomly allocated. Implementation will proceed with unidirectional steps from
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control group to intervention group until all centres are generating graphs of eGFR over time.
The primary outcome for the quantitative evaluation is the proportion of patients referred to specialist renal services
within 90 days of commencing RRT, using data collected routinely by the UK Renal Registry. The qualitative evaluation
will investigate facilitators and barriers to adoption and spread of the intervention. It will include: semi-structured
interviews with laboratory staff, renal centre staff and service commissioners; an online survey of GPs receiving the
intervention; and focus groups of primary care staff.
Discussion: Late presentation to nephrology for patients with ESKD is a source of potentially avoidable harm. This
protocol describes a robust quantitative and qualitative evaluation of a quality improvement intervention to reduce late
presentation and improve the outcomes for patients with ESKD.
Keywords: Chronic kidney disease, Renal replacement therapy, Quality improvement, Evaluation studies
Background
Chronic kidney disease (CKD) is a common long-term
condition that affects up to 14% of adults in England [1].
All patients with CKD are at increased risk of cardiovas-
cular disease [2], and an important minority will develop
progressive renal disease. In the most severe cases (end-
stage kidney disease, ESKD), treatment with kidney dia-
lysis or transplantation (renal replacement therapy, RRT)
is required to sustain life. ESKD is strongly associated
with increased mortality [3]. Although survival rates on
RRT have improved over the last 15 years, the relative
risk of death in RRT patients in the UK in 2013 across
all ages was 6.2 compared with the general population
[4]. Outcomes are particularly poor in those who present
to renal centres with insufficient time to prepare ad-
equately for RRT; the risk of death in such patients is
approximately doubled as compared with those referred
earlier [5], as a consequence of factors including greater
use of temporary vascular access and delayed referral for
transplantation. Late presentation, which is a term con-
ventionally applied in the case of patients first seen by
renal services within 90 days of starting RRT, is therefore
an important cause of avoidable harm. In 2013–2014,
the proportion of patients presenting late varied across
UK renal centres from 4.9 to 33.9%, see Fig. 1 [6]. Redu-
cing this variation is an important target for quality im-
provement activities. Of note, acute kidney diseases can
develop de novo and cause ESKD within 90 days, ac-
counting for 28% of overall late presentation [6]. There-
fore it is impossible to avoid late presentation entirely,
but this should be minimal for the majority of patients
with non-acute renal disease.
A system of graphical surveillance of kidney function over
time (“eGFR graphs”) has been operating at the Heart of
England Foundation Trust in people attending the diabetes
service since 2004 and across the entire population served by
the Trust since 2012. It is the central part of a community-
wide CKD surveillance system that has been associated with
a decline in the incident rate of renal replacement and the
lowest percentage of patients referred late (most recently
4.9%) for dialysis in the UK [6, 7]. The eGFR graph system
identifies patients who are at high risk of requiring renal re-
placement therapy and who otherwise may not have received
timely specialist attention. It is perceived by general practi-
tioners to be easy to use and helpful in improving patients’
management [8]. A similar service implemented in the Kaiser
Permanente system in Hawaii has led to improved outcomes
mirroring those reported from HEFT [9].
Fig. 1 Variation in rate of late presentation to renal services across renal centres in the UK (2013–14). Reproduced with the kind permission of the
UK Renal Registry [6]
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Aims and objectives
The overarching aim of ASSIST-CKD is to drive large-
scale, measurable and sustainable change that reduces
the burden of chronic kidney disease across the UK, and
in particular reduces late presentation for RRT. We
propose to achieve this through the phased imple-
mentation, across locations, of routine surveillance and
reporting of eGFR graphs by pathology laboratories,
thereby facilitating the early recognition and timely
referral in primary care of patients with deteriorating
kidney function.
Methods
Project intervention
Graphical surveillance of all estimated glomerular filtra-
tion rate (eGFR) results analysed within a participating
pathology laboratory, and the reporting in graphical
form of results deteriorating over time to the requesting
clinician.
A dedicated laboratory database operating on an SQL
server integrates blood samples taken in all settings, i.e.,
community and hospital, and merges results stored
under different identifying labels relating to the same
patient. Graphs of eGFR over time are automatically
generated for patients aged ≤65 years with eGFR
<50 ml/min/1.73 m2 and patients >65 years with eGFR
<40 ml/min/1.73 m2 using a dedicated software package,
see Fig. 2 for examples. As eGFR results can be variable
and unpredictable over time, the graphs are reviewed by
a laboratory scientist or renal nurse. Graphs where the
kidney function is clearly deteriorating are flagged.
The graphs from flagged patients are sent to the
referring general practitioner, together with a prompt that
further action, such as referral to specialist renal services,
may be needed. These prompts can be adapted to meet
local needs. The graphs are presented in a format that is
meaningful to patients, and practitioners are encouraged
to share the materials with patients to help increase their
understanding of kidney disease. The laboratories are
encouraged to include links to educational resources for
primary care on progressive CKD with the graphs. A log
of the patients on whom graphs are sent is kept.
Education
Educational and training materials (both project-specific
and generic) are available to participants. Learning events
are being held at regular intervals throughout the life of
the project, to bring together members of the project team
and collaborators from the participating centres to share
experiences and learning.
Laboratory staff
A pack for participating labs has been developed. This
includes a role description for the laboratory staff
reviewing the graphs, a Standard Operating Procedure, a
User Guide, including a “YouTube” summary of how to
run the software and interpret the graphs, and a sum-
mary of the IT specification. For external quality
assessment, all individuals at participating sites who will
be reviewing the graphs are invited to report an anon-
ymised test set of 30 patients’ graphs supplied by the
team at HEFT. The test set included graphs that are
clearly progressive, stable and more nuanced. The out-
come for each interpretation was agreed by consensus
among consultant nephrologists and clinical scientists
after independent review. Before live reporting can
commence the reviewers are required to correctly flag
all 10 of the subset of compulsory graphs showing
clearly progressive CKD and in addition achieve a score
of 80% overall.
The model used at the Heart of England Foundation
Trust (HEFT) is for graphs to be reviewed by a Band 7
Clinical Scientist on the Health and Care Professions
Council register. Review by a renal nurse may be possible
in some locations. Oversight and supervision is provided
by consultant Clinical (or Medical) Scientist. For sites
where other models are proposed these will be examined
on a case-by-case basis by the project team; in all cases a
period of formal training and directly observed working
followed by sign-off by the local consultant Clinical (or
Medical) Scientist lead will be required.
Primary care staff
e-learning resources for primary care are freely available
(http://www.ckdonline.org/ and http://www.theisn.org/
education/education-topics/general-nephrology/item/
2420-free-book-chapters-understanding-kidney-diseases).
Patients
An information booklet on CKD to inform patients and
carers about what the results of an eGFR test might mean
is freely available on-line and practices will be made aware
of it (https://www.kidneyresearchuk.org/health-informa-
tion/resources/looking-after-your-kidneys).
Project design
It is planned that the eGFR graph intervention will
be implemented in laboratories serving at least nine-
teen renal centres across the UK. All sites participat-
ing in this quality improvement programme will
receive the intervention. However implementation will
proceed in a phased stepped wedge manner (“stepped
wedge cluster randomised trial”) to allow a robust
outcome evaluation to be conducted. Without this
design, evaluation of the overall project success may
be overly optimistic due to the phenomenon of
“early-adopters”.
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The unit of intervention in the project is the path-
ology laboratory. However project outcome measures
are aggregated at the level of the renal centre. Where
more than one laboratory lies within the catchment
of a main renal centre, where possible the interven-
tion will be implemented in all these laboratories
simultaneously.
The intervention will be rolled-out sequentially,
with renal centre clusters (and their associated path-
ology laboratories) receiving the intervention at stag-
gered time points. The plan is for four or five renal
centres to begin implementation at each “step”, with
a six-month interval between steps. The time of inter-
vention initiation will be randomised. Crossover is
unidirectional (from control to intervention) so even-
tually all participating centres will implement the
intervention, see Table 1 for a representation of the
step-wedge process.
Approach to adaptations during the project
This is a quality improvement project and adapta-
tions according to local need are expected. We rec-
ognise that there may be delays in securing
agreement from participating sites, and difficulties
with Information Technology. There are a number
of different Laboratory Information Management
Systems (LIMS) in use in the UK, and only one of
these (“Telepath”) has currently been interfaced with
the project software.
We will have a total of four steps, each of six
months duration. In summer 2015 we performed
an initial randomisation (using random number
generation) to an intervention start-time. Due to de-
lays and uncertainties with candidate sites, we per-
formed a first randomisation to select the four
centres in the first intervention step (from ten avail-
able at that time). A second randomisation to
Fig. 2 Examples of the graph intervention generated in the laboratory (a) low but stable function and (b) declining function (Graph 2b would
generate an alert for the clinician as indicated by the red line)
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allocate the remaining 15 centres to the second,
third and fourth randomisation steps was then per-
formed in late 2015.
Recruitment of renal centres
We have preferentially targeted renal centres: with good
completeness of late presentation rate in existing UK
Renal Registry data returns; that are served by a single
laboratory or LIMS; and that have a high proportion of
patients currently presenting late for RRT (as reported
by the UK Renal Registry).
A predefined process for recruitment was followed,
starting with email contact with renal centres and labora-
tories and following up with telephone conversations. In-
clusion in the randomisation to allocate an intervention
start time was performed once we had a formal expression
of interest from both renal clinicians and laboratory scien-
tists together with an indication from sites’ Information
Technology departments that the technical requirements
could be met.
Participating renal centres agree to: submission of vas-
cular access data to the annual UK Renal Registry Multi-
site Dialysis Access Audit; submission of UK Renal
Registry data in a timely fashion; and to provide the UKRR
with the total number of new out-patient renal referrals
(in-centre and outreach clinics) per month. The UK Renal
Registry has Section 251 approval from the Health
Research Authority to collect and hold identifiable infor-
mation without individual patient consent, for patients
with CKD stages 2–5, for audit and quality assurance
purposes. The UKRR have permissions to hold patient-
identifiable data and will hold the final dataset in a
partnership agreement with Kidney Research UK. Access
to the data will not be limited, except patient or centre
identifiable information.
Laboratories will be required to either keep a log of all
patients (containing individual level identifiers) for
whom an eGFR graph is sent to the GP.
Support for participating sites
The project grant includes the initial support necessary
for laboratories to link their pathology systems to the
SQL database and install the software. Training will be
provided for local laboratory staff and staff costs for one
year will be covered. The Heart of England Foundation
Trust experience suggests the annual costs are in the
order of £12,000 per year for a large laboratory serving a
population of one million people. It is expected that the
on-costs from year two onwards will be met locally.
From the outset we have built in mechanisms to achieve
sustainability, working with participating sites to develop
business cases for local commissioners. The business
case focuses on the savings derived from avoidance of
dialysis being re-allocated to pay for the ongoing
provision of eGFR graph surveillance. Experiences from
HEFT suggest that delaying dialysis for one patient for
one year will fund the graph surveillance for a popula-
tion of 300,000 people for approximately 5 years.
Outcome measures
Outcomes will be examined at renal centre level and, if
necessary, laboratory level using Geographic Information
Systems to map patients to laboratories. Routinely col-
lected baseline data will be provided by the UK Renal
Registry and baseline referral rates supplied by partici-
pating centres.
The UK Renal Registry (UKRR) routinely collects and
publishes treatment and clinical performance data for all
adult renal centres in the UK [10]. As part of this, it rou-
tinely receives an extract of data on numbers of patients
starting dialysis in each renal centre and timeliness of
referral.
Our primary quantitative outcome measure is the inci-
dence of late presentation for renal replacement therapy,
defined as any patient first seen by renal services within
90 days of starting renal replacement therapy. These
data will aggregate into six-month time periods, two per
calendar year (Jan to June; July to December).
The following secondary outcomes will be studied:
(i.)the use of temporary vascular access for starting
dialysis
(ii.)latest eGFR measurement, within two weeks before
start of RRT
(iii.)mortality at 6 months from start of RRT in new RRT
patients
Table 1 Study period with randomisation steps
Centres Historical control-periods Periods of core-study
(4 × 6 months) Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec
Jan-2013 - Dec 2014 2015 2015 2016 2016 2017 2017
A – D 0 0 0 0 0 1 1 1 1 1
E – I 0 0 0 0 0 0 1 1 1 1
J – N 0 0 0 0 0 0 0 1 1 1
O – R 0 0 0 0 0 0 0 0 1 1
0=’control’; 1=’intervention’ - eGFR graph surveilence
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(iv.)the incident rate of ESKD, measured annually.
All outcomes measures are routinely collected by the
UK Renal Registry with the exception of vascular access,
which is collected annually as part of the Registry’s
Multisite Dialysis Access Audit.
The number of new patient referrals (per quarter) will
be recorded as a balancing measure. These data are
readily extractable from renal centre appointment
systems.
Statistical analysis plan
Number of participants
We will present numbers of patients flagged to GPs by
each laboratory, per time-period. We will present the
number of patients referred to renal centres and number
of new RRT patients, and these will be presented by
renal centre per time-period. We will also provide a flow
chart of the number of incident RRT patients that will
be included in the analysis after excluding those with
missing data.
Descriptive statistics
The characteristics of individuals by exposure (control
versus intervention) will be presented for each renal
centre.
Analysis of primary outcome
Analysis of changes in risk of late-referral will be
performed using a mixed-effects logistic regression, as a
patient level analysis, with the clustering at renal centres
being accounted for by fitting renal centre as a random
effect. The primary outcome response will be binary (pa-
tient referral <90 days = 1, patient referral ≥90 days = 0).
It is expected that the risk of being late referred should
decrease with the intervention. The odds ratio estimate
of the risk of being late-referred for the treatment effect
(intervention versus control) with 95% confidence inter-
val will be presented (model 1). Analysis will be adjusted
by time-period or step (model 2), and individual pa-
tients’ characteristics such as age at start of RRT, gender,
primary renal diagnosis, ethnicity and deprivation score
(model 3). Due to the nature of the intervention it is
anticipated that its impact on late referral will change
over time, as the risk of being late-referred is expected
to decrease after the intervention is implemented, and
possibly more so with time from start of intervention
(we expect a cumulative effect, at least up to a certain
point). Therefore we aim to explore for possible inter-
action between time and treatment effect (model 4).
The results from model 2 will be considered the pri-
mary result, as our intention is to determine if changes
in the risk of being late-referred for RRT are related to
the intervention and not to an independent time-trend.
Power calculations for the primary outcome have been
derived on Stata [11], based on UKRR data returns from
twelve candidate renal centres. The UKRR reached
complete coverage of the UK in 2007 and data on adult
incident RRT patients have been routinely collected
since then. Therefore we are able to use data on new
incident patients commencing RRT before the project
started, and we plan to include in the analysis the
population of RRT incident patients in 2013–14 for the
participating centres. We therefore used the formula
published by Woertman, which can accommodate the
inclusion of additional historic data [12]. The percentage
of late referral in these twelve centres ranged from 9 to
35%, with an average of 18%. With power set at 80%,
alpha at 0.05 and intra-class correlation (ICC) at 0.05
(based on analysis of UKRR 2013 data) we should be
able to detect a reduction in late presentation rate from
18 to 11%.
Analysis of secondary outcomes
For the type of vascular access used at start of RRT, analysis
will be conducted in the same way as the analysis of
primary outcome (mixed-effect logistic regression of the
binary outcome 0/1, where 0 = permanent access and 1 =
temporary access). This analysis will be performed on all
new patients starting RRT with any treatment modality and
also restricting the cohort to patients starting RRT on
haemodialysis.
Latest eGFR measurement preceding RRT start in new
RRT patients will be analysed using a mixed-effects lin-
ear regression model. Transformation of the response
variable ‘eGFR’ may be necessary to achieve a normal
distribution prior to analysis. The same model building
sequence will be used as for the logistic analysis of the
primary outcome.
The analysis of the six months mortality in new RRT
patients will be conducted in the same way as the
analysis of the primary outcome, using a mixed-effect
logistic model (binary outcome, 0 = alive after 6 months
from start of RRT, 1 = died in the 6 months following
start of RRT).
The incidence rate of RRT (expressed as number of
patients starting RRT per million population), will be
analysed using Poisson regression. This will be a cluster-
level analysis, with one measure per time-period per
renal centre.
Qualitative evaluation
The aim of the qualitative evaluation is to understand
the experiences of those directly involved in the
intervention, including laboratory staff, primary care
staff, clinicians in renal centres and patients. In addition,
the experiences of commissioners in facilitating and
monitoring the intervention will be sought. The
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qualitative evaluation plan is based on previous learning
from feedback at the Heart of England Foundation Trust
(HEFT) in October 2014.
Laboratory staff
One-to-one semi-structured interviews lasting 20–30
min will be conducted with 1–2 laboratory staff in each
Trust, either face-to-face or by telephone. Questions will
explore the experiences of being involved with the eGFR
project, and will include discussion of: what specifically
has worked/not worked; how far the training has
equipped staff to undertake this new role; and potential
recommendations for other labs who will be developing
the system in the future. Data will be analysed using
simple thematic analysis.
Primary care staff
We will conduct an electronic survey, via SurveyMonkey,
of a sample GPs who have been sent an eGFR graph. The
overall aim of the survey is to determine if the interven-
tion is effective and how far it might impact on a patient’s
clinical care. Questions asking about timeliness, usefulness
and ease of interpretation will be answered on a Likert
scale. Open questions asking about possible impact on pa-
tient care and recommendations for future enhancements
to the eGFR system will be answered in free text. Quanti-
tative data will be analysed using simple descriptive statis-
tics; free text will be analysed by simple thematic analysis.
One GP surgery in each stage of the intervention roll-
out will be approached for an in-depth evaluation. This
will involve a focus group with a variety of staff in the
practice (GPs, nurse practitioners, practice nurses,
practice managers) who may be involved with the inter-
vention. Questions will be open and will commence with
‘What is your experience of using the eGFR system in
this practice?’, but will move to further questions around
timeliness, usefulness and patient experience. Focus
groups will be recorded, data transcribed and analysed
using simple thematic analysis.
Renal centre staff
Short face-to-face or telephone interviews will be re-
quested and conducted with one nephrologist and one
other staff member (eg. clinical nurse specialist or nurse
consultant) who are involved in seeing patients who
have been referred following GP review of the eGFR
graph. Questions will focus on practicalities, such as bar-
riers and enablers of adoption, and sustainability within
the renal centre. Notes of the interviews will be taken
and common themes identified.
Commissioners
Telephone interviews will be conducted with one CCG
commissioner or quality improvement lead in each
Clinical Commissioning Group (CCG)/Strategic Clinical
Network (SCN). Interview questions will focus on im-
pressions about barriers and enablers to adoption across
the CCG/SCN, cost-effectiveness, sustainability and
spread.
Economic evaluation
The cost of implementing the intervention will be
estimated from the study and existing published costs
retrieved for renal outpatient attendances and renal re-
placement therapy options. Utility index values will be
identified from the literature for the various health states
possible and used to estimate cost per quality adjusted
life year gained from the intervention. A NHS health
care perspective will be adopted.
Patient and public involvement
We have convened a Patient Project Team (PPT), following
a successful model developed by members of the project
team in a previous quality improvement project [13]. The
PPT chair is an integral member of the Core Operational
Team, providing patient leadership and contributing on an
entirely equal footing to healthcare professionals. Terms of
Reference and role descriptions were drawn up and signed
off by team members. Members of the group will be
reimbursed in accordance with National Institute for
Health Research Guidelines [14]. The PPT will: guide and
influence the development and delivery of all patient-facing
materials within the project; work locally and nationally to
facilitate adoption, spread and sustainability, using the
power of the patient and carer voice to influence the
commissioning process; work closely with healthcare
professionals in the design and delivery of the project evalu-
ation; and represent the patient and carer voice at national
or local meetings.
Project funding
Funding for the implementation of the ASSIST-CKD
intervention for one year and a full quantitative and quali-
tative evaluation was awarded by the Health Foundation
(Registered Charity 286967) to Kidney Research UK (Reg-
istered Charity 252892). Kidney Research UK will provide
project governance and administration. The project is
supported by the following partner organisations: Renal
Association; British Renal Society, British Kidney Patient
Association; National Kidney Federation and the Royal
College of General Practitioners. The evaluation will be
delivered through a collaboration between the School for
Health and Related Research (University of Sheffield), the
UK Renal Registry and London South Bank University.
The project has been funded by the Health Foundation
as a part of their “Spreading Improvement” programme,
the purpose of which is to support organisations to de-
velop projects based on interventions developed with
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previous Health Foundation funding that have already
demonstrated improvements and have potential to be
transferable to realise greater benefits to the wider
health service. However it is recognised that quality
improvement projects may demonstrate initial success
due to specific features of the local context and robust
evaluation of a subsequent roll-out is then required to
demonstrate continued efficacy outwith the context in
which the intervention was originally developed. In
addition, it is important to confirm that change does not
merely reflect underlying temporal trends. The project
was considered by the National Research Ethics Service
(South East Coast-Surrey) and determined to be service
evaluation, not requiring ethical review by an NHS
Research Ethics Committee.
Project oversight
An Advisory and Dissemination Board (ADB) has been
established to provide directional stewardship to achieve
spread and scale. The role of the ABD will be critical for
dissemination and in linking the project to policy
change. In addition, an Evaluation Advisory Group will
oversee the project evaluation, ensuring that quantitative
and qualitative elements are brought together to provide
advice on risk/change management.
The project has been registered with the International
Standard Randomised Controlled Trials Number
(ISRCTN) Registry, registration number 13701669.
Authorship
Those playing a major role in the design, conduct and
evaluation of the intervention will be eligible for author-
ship of subsequent publications. These will be written by
the research group and we will not use professional
writers.
Discussion
Guidelines on the identification and management of
CKD that include referral criteria for primary care were
issued by the National Institute for Health and Care Ex-
cellence in 2008 and revised in 2014 [15]. However
cross-sectional data indicate that people with earlier but
progressive disease are frequently not recognised and re-
ferred by primary care, and that many patients with
more advanced but stable disease continue to attend
hospital clinics where ongoing specialist input may result
in little added value [16].
This suggests that there are significant opportunities
for better interaction and integration between primary
and secondary healthcare services in the UK to improve
the quality and efficiency of kidney care. Late referral for
renal replacement from primary care is an important
cause of morbidity and mortality amenable to healthcare.
Following the introduction of eGFR reporting and the
inclusion of CKD within the UK pay-for-performance
scheme for general practice there has been a steady de-
cline in the proportion of patients presenting late for
RRT, from 26–30% during 2000–2005 [17] to 18% in
2014 [6]. However the highest performing UK renal
centres, which include the site at which the eGFR graph
intervention was developed and tested, achieve late pres-
entation rates of less than 10% [6]. Therefore evaluating
the spread of the eGFR intervention to other centres is
an appropriate focus for improvement activities.
Local evidence suggests that the graphical surveillance
of kidney function is associated with measurable
improvements in care [7, 8]. This project is applying a
stepped wedge approach to the dissemination of the
eGFR graph intervention, in order to scale up these
improvements and to determine the effectiveness of the
intervention away from the environment in which it was
developed. The critical role of context in improvement
work is well-described [18]. A stepped wedge design is
particularly appropriate for the evaluation of interven-
tions during routine implementation [19], and will
complement the concurrent roll-out of the eGFR graph
intervention across the West Midlands that is being
funded by NHS England via the West Midlands Strategic
Clinical Network and Clinical Senate [20].
Our statistical model balances the competing effects
on power of the number of steps and the length of time
between steps [21]. The quantitative analysis will be
strengthened by the availability of a minimum of
2.5 years of high quality routinely collected baseline data
at all sites, and supported by a qualitative element that
will explore the barriers and enablers of change and the
perceptions of the participants as described above.
The role of ethical oversight of quality improvement
projects has been the subject of heated debate over recent
years [22]. Recent reviews have emphasised a principle-
based rather than a rule-based approach to determine
whether an activity requires formal ethical approval, with
the key elements including: the risks and benefits to exist-
ing or future patients; the need to respect individuals’
rights to self-determination; the preservation of privacy
and confidentiality; and the distribution of the activity
across patient groups [23]. The project team carefully con-
sidered these issues internally. It was recognised that the
risks and burdens to patients were minimal. The project
uses existing biochemical data within the laboratory and
outcome measures are routinely collected. There is no al-
location to different interventions across patient groups:
due to the stepped-wedge design all participants receive
the intervention by the end of the project. However, we
also recognised that the project evaluation would generate
new knowledge potentially relevant to the health service
more widely. Accordingly we sought external advice, from
both a former ethics chair and an independent expert.
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Their opinion was that the project appeared not to meet
the criteria for research, but that a formal opinion from an
Ethics Committee would be helpful. We therefore pre-
sented the project to the National Research Ethics Service
for consideration (South East Coast-Surrey Committee):
the Chair’s opinion was that the project was a service im-
provement/evaluation and did not require ethical
approval.
Given the extreme financial constraints under which
the UK National Health Service is currently operating, it
is imperative to perform a robust evaluation of any qual-
ity improvement intervention. The proposed evaluation
will ensure that the project is delivering improvement as
expected and therefore represents an appropriate use of
scant resource. It will also help to inform the aformen-
tioned sites where the eGFR graph intervention is being
introduced routinely outside the project [20].
The project has limitations and challenges. We recognise
the complexities inherent in a stepped wedge approach,
from both an analytical and operational perspective. The
follow up is quite short and we do not have time to have a
transition phase immediately following implementation of
the intervention. We will not be performing interim
analyses and believe that it is very unlikely that anything in
these analyses would give good grounds to change the
duration of the steps. However the number and duration of
steps will be reviewed by a project Evaluation Advisory
Board, if needed, as dictated by operational and logistical is-
sues. There are several laboratory IT systems in operation
across the UK and the need for the eGFR graph system to
work across multiple platforms may impact upon the pro-
ject time-lines. Delays will be mitigated by over-recruitment
and pre-allocation of intervention start time at the point of
formal expression of interest.
The UK pathology laboratory environment is evolving.
The Audit Commission called for pathology services to be
re-organised in 1993, but changes have been slow to be im-
plemented. “Hub and spoke” models were recommended
in Lord Carter’s 2008 review of pathology services, where
routine (including GP) work is consolidated into large hubs.
This model offers both opportunities and threats. Consoli-
dation of high volumes of GP samples into a single labora-
tory/laboratory cluster will allow a single site deployment of
our intervention to reach far larger numbers of surgeries.
The risks are that historic pathology data may not be trans-
ferred to new systems, preventing the retrospective charting
of renal function, and that there may be pathology reorga-
nisations at participating sites within the project lifespan.
Routinely collected data are readily available and inex-
pensive, but have inherent weaknesses when compared
with trial data: they can be incomplete and subject to
bias, and may not collected or reported uniformly across
different sites. Although the unit of intervention in the
project is the pathology laboratory, UK Renal Registry
data are aggregated and reported at the level of the renal
centre. If sites are recruited where not all laboratories
serving a main renal centre implement eGFR graph
reporting, it is theoretically possible to map late presen-
ting patients to laboratories using Geographic Informa-
tion Systems; however this process is imperfect and
subject to significant inaccuracies as a result of boundary
effects.
We recognise that generating enthusiasm for improve-
ment activity within the current financial envelope in the
National Health Service may be challenging. Although
participating sites will be fully supported to deliver the
intervention for one year, achieving sustainability beyond
one year will require support from local commissioners,
which we anticipate will be contingent on evidence of the
cost-effectiveness (or potential cost-effectiveness) of the
intervention. Exploring the drivers and barriers to lasting
change will be a key output of the qualitative element of
our evaluation. It should also be recognised that there is
an irreducible minimum late presentation rate as a result
of renal failure that develops acutely, as seen for example
with myeloma kidney [24].
The provision of an eGFR graph surveillance service is
a conceptually simple quality improvement intervention
that we believe should benefit both patients and clini-
cians. By its nature it is well-suited to replication at
other sites. Set against the annual cost of haemodialysis,
the system has clear potential to be highly cost-effective.
A demonstration that it is self-sustaining and effective
across a range of contexts would create a powerful case
for universal adoption of the service.
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